ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Because IGF-IR is dispensable for the activity of HSCs but regulates BCR/ABL leukemia cell fates and supports self-renewal of CML cells, targeting IGF-IR may be an ideal anti-leukemia strategy.